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Abstract
Aim: To investigate the enhancement of humoral immunity when CpG ODN (cytidine phosphate guanosine
oligodeoxynucleotides) and aluminium adjuvants are complexed with the HCV (Hepatitis C virus) recombinant
immunogen in mice.
Methods: After immunizing Balb/c mice with the recombination HCV antigen adjuvanted with pUCpGs10 and/or
aluminium(antigen+CpG+alum, antigen+CpG, antigen+alum, antigen+PBS), enzyme-linked immunosorbent assay
(ELISA) was used to measure the specific serum antibody titers of IgG, to determine the neutralization response to
various peptide genotypes, and to determine the concentration of IL-6 and IL-10 in supernatants of in vitro
cultured splenic lymphocytes. Enzyme-linked immunospot assay (ELISPOT) was used to quantify the non-specific
and specific splenic antibody-secreting cells (ASCs), and flow cytometry (FCM) determined the ratio of different
splenic lymphocytes. The serum of rabbits immunized with the recombinant pBVGST/HVR1 antigen
immunoprecipitated the HCV isolated from 12 patients’ serum.
Results: The sera antibody titers were 1:51200, 1:9051, 1:18102, 1:6400 respectively after the final immunization and
demonstrated good neutralization responses to the six gene peptide containing 1a, 1b, 2a, 3a, 4a and 6a. The
aluminum adjuvant increased the population of both specific ASCs (P < 0.01) and total ASCs(P < 0.05), with a
proportional rise in concentrations of CD19
+CD27
+ (P < 0.05), as well as levels of IL-6, IL-10 (P < 0.05) in splenic
lymphocytes. The results clearly indicated a significantly higher number of CD19
+CD38
+ splenic lymphocytes with
the aluminum and pUCpGs10 adjuvant present compared to the control group(P < 0.05). Anti-HVR1 antibody in
induced mice can cross-reactively capture HCV particles (10/12).
Conclusions: 1. The aluminum adjuvant induces a potent Th2-biased immune response by increasing both the
populations of specific and total ASCs and the ratio of CD19
+CD27
+ cells. 2. The pUCpGs10 complexed with the
aluminum adjuvant boosts the population of plasma cells and increase the efficiency of the immune response. 3.
The two adjuvants have synergistic effects on humoral immunity. 4. The recombinant HVR1 protein has the
possibility of generating broadly reactive anti-HVR1 antibody.
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At present, more than 200 million people worldwide are
infected with HCV [1], and are therefore at risk of
developing liver cirrhosis and hepatocellular carcinoma.
HCV has been shown to impair the humoral immunity
response in several ways [2,3]. For example, HCV can
induce resistance of infected hepatocytes to type I IFNs
and HCV E2 inhibits NK cells. Viruses escape from
immune responses through mutation in antibody and T
cell epitopes has been shown for both HCV-infected
humans and chimpanzees. In addition, potential
mechanisms include reduced T-cell priming with a
potentially altered DC(dentritic cell) function and inhibi-
tion of macrophage, DC and T-cell function through
binding of the HCV core protein to the receptor for the
complement component C1q(C1qR).
The constant changes that occur to HCV variants
make it difficult to neutralize the virus and develop vac-
cines based on a single specific antibody. However, an
effective vaccine enhances host humoral immune
responses in an antigen-specific manner by producing a
broader spectrum neutralization antibody. Various pep-
tides containing the B and T cell epitopes have been
synthesized, such as recombinant polyprotein HVR1 and
E1(HVR1: VARAAFGLTSIFSPGAKQN, GTHVTGGK
VAYTTQGFTSFFSRGPSQK, QTTVVGGSQSHTVRG
LTSLFSPGASQN, TTHTVGGSVARQVSHLTGLFSPG
PQQKGSASSSEGGSTTTTTGGVQGHTTRGLVRLF
SLGSKQN; E1: YQVRNSSGLYHVTNDCPNSS, YEVRN
VSGVYHVTNDCSNSS, VQVKNTSSSYMVTNDCSNDS,
LEWRNTSGLYVLTNDCSNSS, VHYRNASGVYHVTN
DCPNTS, LTYGNSSGLYHLTND CPNSS.) involving
different genotypes and variations of the quasi-species
which conclude 6 kinds of genotype and the response
rate to the sera of the HCV infected patients is more
than 90% [4,5]. In order to obtain higher titers of the
antibody to the polyprotein, adjuvants are essential.
Adjuvants augment the immunological response of an
organism by enhancing humoral immunity in different
ways [6]. There has been study about cellular mechan-
ism of coupling CpG and aluminum to HBV instead of
humoral mechanism to HCV [7].
1.1. pUCpGs10
When CpG ODN is applied as the adjuvant of the HCV
vaccine it significantly stimulates innate immunity by
specifically binding pDC TLR9 to B lymphocyte [8,9], as
i st h ea g o n i s to ft h et o l l - l i k er e c e p t o r9 ( T L R 9 ) .C p G
ODN has great potential to be used as a vaccine adju-
vant or a modulator of immunotherapy. For example,
TLR9 signals can regulate B lymphopoiesis in vivo [10].
pUCpGs10 which is fabricated by the institute of Basic
Medical Sciences (patent No.200710110466.7)containing
eleven motifs of CpG inserts repeating ten times in the
pUC19 vector, which was invented by this research
group, and directly activates signal transduction causing
cell division and cytokine secretion. pUCpGs10 shows
adjuvant activity towards almost all of the protein anti-
gens and inactivated vaccines. The main contributions
of CpG ODN include the promotion of the cytokine
secretion(IFN-a/b, g)and anti-virus reaction, increases in
NK cell and macrophage cytotoxicity, enhancement of
antibody titer, elevation of the expression of MHC and
immune cofactors, and increase the Th1 cellular immu-
nologic response to antigenic specificity [11]. Mouse B
cells express a number of different toll-like receptors
(TLRs) including TLR3, TLR4, TLR7 and TLR9. The sti-
mulation of mature B cells with TLR ligands induces B
cell activation, proliferation and differentiation into anti-
body secreting cells [12-15].
1.2. Aluminum
Aluminum hydroxide is the only inorganic adjuvant cur-
rently in use. It is approved by the US FDA for vaccine
formulation and has a very good safety profile. Any
adverse reaction to aluminum adjuvant is not clinically sig-
nificant and is localized to the injection site [16,17]. Alu-
minum induces the Th2 immune response in animal
models, stimulates proliferation of T cells in vitro,p r o -
motes differentiation of histoleucocytes into mature CD83
+DCs, and proliferation of macrophages originating from
bone marrow in vivo[18]. Aluminum hydroxide is posi-
tively charged at pH 7.4 and easily absorbs onto negatively
charged antigen [19]. The regional accumulation com-
bined with delayed release stimulates an effective and sus-
tained B lymphocyte immune reaction [20,21].
1.3. Specific antibody-secreting cell
Naïve B cell contacted antigen with BCR (B cell recep-
tor), then it proliferated into the antigen specific B cell.
The specific B lymphocytes ultimately differentiate into
plasma and memory B cells in the germinal center. In
the second immune response, memory B cells absorb
and present antigen as APC to the memory Th cell. The
activated Th cells express multiple membrane molecules
and show enhanced secretion of cytokines, which
induces the memory B cells to quickly proliferate and
differentiate into plasma cells, that actively biosynthesize
and secrete antibodies [22].
The current consensus is that BCR interacts with T
cell to help promote B cell differentiation and prolifera-
tion to the antigen-specific B cell, and then on to the
memory B cells or plasma cells. Through affinity
maturation, plasma cells ultimately differentiate into
antibody secreting cells (ASCs) [23]. Memory B cells
can be activated, amplified, and selectively transformed
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TLR9 naïve B cells, the memory B cells constitutively
express TLR9 and differentiate into immunoglobulin
secreting cells when stimulated with CpG ODN [24].
The memory B cells can quickly differentiate and pro-
liferate at any time during the secondary immune
response. Unlike naïve B cells, the activation of memory
B cells required a stimulation signal not only from Th
but also BCR. The quantity of peripheral blood lympho-
cytes in patients persistently infected with HCV is
reduced compared to healthy individuals and those who
spontaneously recover from HCV infection. These dif-
ferences may result from the weakening of post-stimulus
humoral immunity and reduced quantity of specific ASC
in vitro [25].
1.4. CD19
+CD27
+ and CD19
+CD38
+ cells of mice
CD19 is an important molecule within the B lymphocyte
antigen receptor (BCR) complex that regulates signal
transduction [26]. The early pro-B cells of mice express
CD27
+AA4.1
+1/
-Ki-67
+ Ly-6C
- Ly-6A/Sca-1
lo/
-Thy-1
-
2CD43
+CD4
+/
-2CD16/32
lo/- and CD44
Hi. Recent find-
ings show that expression of CD27 permits the distinc-
tion between antigen-inexperienced naïve B cells and
antigen-experienced memory B cells [27]. It is known
that the frequencies of CD27
+B cells in persistently
infected patients are reduced and that CD27 ligation
inhibits terminal differentiation of murine B cells into
Ig-secreting plasma cells [24]. CD19 is the main marker
of murine B cells and antibodies to mouse CD38 acti-
vate B lymphocytes in adult mice [28,29]. Both naive
and memory B cells progress to a plasma-cell pheno-
type:CD19
lowCD20
lowCD27
+CD38
+HLA-DR
low [30].
CD38 is a marker for human bone marrow plasma cells
and has been used extensively to monitor in vitro gen-
eration of ASCs from memory B cells. Crosslinking of
CD38 not only induces the proliferation of mature folli-
cular B cells but also enhances the proliferation and dif-
ferentiation of the immature transitional 2 (T2) B cells.
Biological outcomes after crosslinking CD38 on imma-
ture and mature mouse B cells are dependent on
expression of a functional BCR [31]. The crosslinking of
CD38 in mature B cells can be induced by toll-like
receptor (TLR) signaling. Likewise, crosslinking of
mature mouse B cells with anti-CD38 in the presence of
cytokines such as IL-4 induces proliferation [27], while
activation of B cells with anti-CD38 in the presence of
IL-5 induces differentiation of B cells into IgG1-secret-
ing plasma cells [32]. Specifically, CD38 catalyzes an
ADP-ribosyl cyclase reaction, and likely plays an impor-
tant role in inflammatory responses [33]. It is well
known that foreign CpG-DNA from viruses and bacteria
can activate memory B cells through binding to TLR9,
and that this pathway may be involved in the
continuous activation of memory B cells ensuring life-
long humoral immunity [34]. In this study, the quantita-
tive ELISPOT method for simultaneous estimation of
single-cell IgG secretion rates and secreting cell frequen-
cies in human B cell populations was used. These results
suggest that CD27
+IgM
_ memory B cells activated with
CpG and cytokines exhibit considerable heterogeneity in
IgG secretion rates, and two major secreting subpopula-
tions were identified. BCR cross-linking reduced the fre-
quency of cells with high per-cell IgG secretion rates,
and this was associated with a parallel decrease in
CD27
high B cell blasts. Increased cell death may account
for the BCR-stimulated reduc t i o ni nh i g h - r a t eI g G - S C
CD27
high B cell blasts [35].
2. Methods
2.1. Purification of antigen and immunization of Balb/c
mice and rabbits
Activation of the genetically engineered bacteria, expres-
sion and purification of the HCV recombinated antigens
pBVIL1/E1 and HVR1 were undertaken as previously
described [3,4].
Female Balb/c mice, aged 6-9 weeks were obtained
from the experimental animal center of the Academy of
Military Medical Sciences (Beijing, China). Rabbit (New
Zealand, weight: 3 kg) were obtained from KeYu breed
factory of Beijing. The animals were housed and manipu-
lated according to the Care and Use of Laboratory Ani-
mals (China), and kept under pathogen-free conditions.
T h em i c ew e r er a n d o m l ya s s i g n e di n t of o u rg r o u p s
and injected s.c. with 50 μgE 1a n d5 0μg HVR1 +100
μl colloidal(Al(OH)3,1:1, v/v; Therma Scientific) together
with 20 μg pUCpGs10, 50 μgE 1a n d5 0μgH V R 1+ 2 0
μg pUCpGs10, 50 μgE 1a n d5 0μgH V R 1 + 1 0 0μlA L
(OH) 3,5 0μgE 1a n d5 0μg HVR1 formulated in PBS.
The rabbits were injected (s.c.) with 100 μg HVR1 +110
μl colloidal(Al(OH)3,1:1, v/v; Therma Scientific)
together with 20 μg pUCpGs10.
An interval of 4 weeks was employed for the second
and third immunizations. All mice and rabbits were
exsanguinated 2 weeks after the last immunization.
Mice spleens were removed and splenocytes were ana-
lyzed using the enzyme-linked immunospot (ELISPOT)
assay and the flow cytometry (FCM). Serum samples at
2, 6 or 10 weeks after immunization of mice and rabbits
were tested for specific antibody titers.
2.2. ELISA assay
Sera were collected two weeks after the last immuniza-
tion from vaccinated mice. IgG antibody titers in serum
samples were assessed using a standard ELISA protocol.
Briefly, microtiter plates were coated overnight at 4°C
with 5 μg pBVIL1/E1 or HVR1 and synthesized peptide-
sE1a, E1b, E2a, E3a, E4a and E6a were added in 100 μl
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The plates were washed thoroughly with PBS containing
0.05% of Tween-20 (PBST) and then blocked with 110
μl of PBS containing 20% goat serum albumin for 8 h at
room temperature. Two-fold serially diluted serum sam-
ples were allowed to react with coated plates at 37°C for
30 min, followed by 0.05% PBST washes. They were
then incubated with a 1:10000 dilution of horseradish
peroxidase conjugated goat anti-mouse IgG antibody
(Bio-Rad) at 37°C for 20 min. After washing the plates,
100 μl of TMB was added to each well to allow colour
development at room temperature for 10 min before the
reaction was stopped by adding 50 μlo f2 MH 2SO4.
Absorbance was measured at 450 nm using an IEMS
reader. Antibody titers were expressed as the reciprocal
of the last sample dilution giving an absorbance of at
least two-fold that of the pre-immune sample and with
an OD ≥ 0.20.
The concentration of IL-6 and IL-10 was determined by
ELISA from the four groups of four mice and single-cell
suspensions were prepared. After lysing red blood cells
with Tris-NH4Cl, splenocytes (5 × 10
6 cells in 200 μl)
were cultured at 37°C with E1+HVR1 recombination anti-
gen (20 μg/ml)or LPS(1 μg/ml) in vitro, using the ELISA
assay to measure the titer of IL-6 and IL-10. Results are
shown as the mean value obtained for duplicate wells.
2.3. ELISPOT assay
Specific antibody secreting cells of E1 and HVR1 were
quantified using an ELISPOT kit (Mabtech AB, Nacka
Strand, Sweden). Multi Screen 96-well filtration plates
MAIP S4510 (Millipore, USA, Masarzsa) were coated with
100 μlo fa5 0μg/ml pBVIL6/E1 or pBVIL1/GST1+8
HVR1 dilution and 15 μg/ml anti-mouse IgG antibody
dilution overnight at 4°C. Samples were then washed with
ELISPOT coating buffer and blocked for 2 h with 200 μl
RPMI1640 containing 10% Fetal bovine serum. After
clearing red blood cells with Tris-NH4Cl, splenocytes (1 ×
10
6/well) were cultured for 24 h in RPMI-1640 alone
(negative control). After removing cells and washing with
wash buffer (PBS, 0.1% Tween 20), 100 μlo f1μg/ml bioti-
nylated anti-IgG in PBS containing 0.5% fetal bovine
serum dilution was added and incubated for 1 h at room
temperature. After washing, BCIP/NBT-plus substrate
solution was filtered by passing through a 0.45 μm filter
and added (100 μl/well) until the spots appeared at room
temperature. After rewashing, spots were then counted
using an immunospot image analyzer. Results are shown
as the mean value obtained for duplicate wells.
2.4. Flow cytometric analysis following surface staining of
splenocytes
Two weeks after the final immunization, spleens were
harvested from four groups of four mice and single-cell
suspensions were prepared. After lysing red blood cells
with Tris-NH4Cl, splenocytes (5 × 10
5 cells in 200 ml)
were cultured at 37°C with monoclonal antibodies direc-
ted against CD19, CD27 and CD38, namely anti-CD19-
APC, anti-CD27-PE and anti-CD38-FITC(1 μl/well;
Bioscience) as positive controls. The normal mice and
anti-human CD19-APC served as negative controls.
After 30 min, cells were washed and analyzed on a
FACS Calibur flow cytometer (Becton Dickinson Immu-
nocytometry Systems). For all flow cytometric analyses,
the data (n = 4) are presented as means ± SD.
2.5. Immunoprecipitation
The virus capture activity of antisera was assessed by the
modified method for immune complex analysis of HCV in
patient sera. 100 microliters of 12 diluted patients’ sera
were centrifuged at 14 000 g for 15 minutes, and the
supernatants were separately mixed with 5 μlo ft h ep o l y
anti-HVR1 IgG, which were purified from the immuniza-
tion rabbits’ serum with protein G sepharose. The mix-
tures were incubated for 4 h at 4°C, and then 5 μlo f2
mg/ml goat anti-rabbit IgG(Sigma)was added. After a sec-
ond incubation period of 1.5 h at 4°C, the mixture were
centrifuged at 2800 rpm for 15 min and separated into
supernatants and pellets. To examine the capture activity
of the anti-sera semiquantitatively, both the supernatant
and the pellet were tested for HCV RNA by enzyme
immunology assay combined RT-PCR(established by this
laboratory). This method will be described next.
2.6. RT-PCR
RNA was extracted with Trizol(Life Technologies). A
RT and a two-step PCR assay with nested primers were
performed to detect the 5’-untranslated region of HCV
RNA. The external pair of primers were F1 5’CG CTC
GAG TTT GCC GGC GTT GAC G 3’and R1 5’CG
TCT AGA AGT CCT GTT GAT GTG CC-3’.T h e
sequence of the internal pair of primers were F2 5’-CG
CTC GAG TTT GCC GGA GTT GAT G-3’and R2 5’-
CG TCT AGA GGT CCT GTT GAT ATG CC-3’.I na
20 μl RT reaction system, 50 pmol of each external pri-
mer and 200 μmol/L dNTP were added. After denatura-
tion for 5 minutes at 70°C, the mixture was bathed in
ice immediately for 2 minutes. Then, 2U AMV (Prome-
gar)was added, and the RT reaction was performed at
42°C for 1 hour. In the first step of PCR, the external
pair of primer was used, and the cDNA was amplified in
a2 3μl reaction mixture with 300 cycles of 30 s at 94°C,
30 s at 55°C and 30 s at 72°C each, followed by an
extension for 5 minutes at 72°C at the end. In the sec-
ond step, the internal pair of primer was used and 32
cycles were performed with each cycle of 30 s at 94°C,
30 s at 55°C and 30 s at 72°C, followed by an extension
of 5 minutes at 72°C.
Zhan et al. Virology Journal 2011, 8:507
http://www.virologyj.com/content/8/1/507
Page 4 of 10Statistical analysis
Statistical analyses were performed using SAS 8.0 soft-
ware. Results are presented as means ± standard errors.
The statistical significance of the differences between
the means of the experimental groups was tested by the
Student t test for unpaired data. A difference was con-
sidered statistically significant when P < 0.05.
3. Results
3.1. Combined immunization with pUCpGs10 and Al (OH)
3: the aluminum-induced humoral immune reaction
Differences between the four groups in terms of the
induction of antigen-specific serum antibodies were
strongly indicated since the mean titers of the four
groups were 1:51200, 1:9051, 1:18102, 1:6400. To induce
B-cell responses in vivo,m i c ew e r ei m m u n i z e d( i / m )
with the HCV polyprotein and different adjuvants. We
found that the HCV polyprotein alone induces very low
antigen-specific serum antibodies. In contrast, mixing
the HCV polyprotein with the pUCpGs10 adsorbed to
Al(OH)3 gel adjuvant induced the highest antibody
responses. To determine whether differential specific
responses were induced to each genotype component of
the polyprotein, the serum antibody responses against
each of the peptides (E1a, E1b, E2a, E3a, E4a and E6a)
were measured [3] in the group immunized with Al
(OH)3. These results demonstrate that serum antibody
titers were greatest against the E1b and E1a peptides
(Figure 1), where as the serum antibody responses were
relatively low against the E3a and E4a, amounting to
two orders of magnitude lower than anti-E2a and E6a
titers. This data also conceived that, with majority of the
antibody response being against the 1a and 1b genotypes
for the folded conformation of the recombination poly-
protein, although the expressed and purified E1 polypro-
tein was immunogenic in mice adjuvanted with
pUCpGs10 and Al (OH)3, the response against each of
the genotypes was different. The genotype 1a and 1b are
most popular in China (40%, 16%). These results indi-
cated that Al(OH)3 and pUCpGs10 plasmid combination
stimulated a robust and long-term humoral immune
response and also showed a synergistic effect. This is
consistent with other reports that combination of
pUCpGs10 with conventional adjuvants, such as Quil A
[36], liposome [37], MPL and IFA/CFA [38], elicit syner-
gistic antibody responses in mice.
3.2. Combined immunization with pUCpGs10 and Al(OH)3
induces the largest population of specific antibody
secreting cells as assessed by the ELISPOT assay
As a measure of B-cell responses, IgG-secreting
responses in the spleen were measured after immuniza-
tion with HCV polyprotein and adjuvants. In order to
distinguish which adjuvant with the polyprotein were
the most immunogenic, Tris-NH4Cl was used to isolate
lymphocytes by the red cells. The total ASC (antigen
secreting cell), which is also called functional plasma
cell, contain antigen specific ASC and unspecific ASC.
The population of the specific ASCs were 66.13 ± 26.66,
40.25 ± 22.22, 62.88 ± 17.06, 24.13 ± 14.90 SFU/10
6; the
Figure 1 Serum anti-E1a, E1b, E2a, E3a, E4a and E6a IgG responses following immunization with E1+HVR1 with pUCpGs10 and
aluminium. Five mice per group were immunized i.m. twice with a 4 week interval. The mice were bled 2 weeks after the third immunization
to collect sera for the ELISA. The data are presented as mean serum IgG titres ± SD.
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50.58, 125.75 ± 27.36, 42.50 ± 38.54 SFU/10
6. Immuni-
zation with pUCpGs10 and aluminum induced the high-
est frequency of both IgG-secreting cells and total
antigen secreting cells, while immunization with the
HCV polyprotein alone induced the lowest frequency of
IgG-secreting cells and total antigen secreting cells (Fig-
u r e2 ) .T h er e s u l ts h o wt h a ta l u m i n u mc a nm a r k e d l y
increase the population of specific ASC (P < 0.01, F =
9.93) and total ASC (P < 0.05, F = 5.58) (Table 1). The
proportion of specific ASC to total ASC were 59.4%,
55.14%, 50% and 56.76% (P < 0.05). This data
Figure 2 The result of ELISPOT, FCM and ELISA of the spleen lymphocyte in BALB/c mice (mean ± SD). The application of aluminium
have statistical significance of the population of the CD19
+CD27
+ B cell and CD27
+CD38
+cell. (P < 0.01, P < 0.0001). The population of the CD19
+CD38
+ B cell of Alum+CpG to the PBS group have statistical significance.(P < 0.05). The concentration of IL-6, IL-10 in cultivated supernatant of
the splenic lymphocytes of the BALB/c mice after the incentivation of HCV antigen in vitro(mean ± SD)The concentration of IL-6 and IL-10 was
determined by ELISA from the four groups of four mice and single-cell suspensions were prepared. After lysing red blood cells with Tris-NH4Cl,
splenocytes (5 × 10
6 cells in 200 ml) were cultured at 37°C withE1+HVR1 recombination antigen (20 μg/ml)or LPS(1 μg/ml)in vitro, using the
ELISA assay to measure the titer of IL-6 and IL-10. Results are shown as the mean value obtained for duplicate wells.
Table 1 IgG-secreting cells and total antigen secreting cells produced by immunization with pUCpGs10 and
aluminium.
Group ELISPOT assay(SFU/10
6) FACS(%) ELISA
Specific ASC Total ASC CD19
+
CD27
+
CD19
+
CD38
+
IL-6(pg/ml) IL-10(pg/ml) IgG titer
CpG+Alum 66.13 ± 26.66 111.25 ± 44.77 2.06 ± 0.34 46.42 ± 2.21 31.14 ± 34.57 249.75 ± 175.35 1:51200
CpG 40.25 ± 22.22 73 ± 50.58 1.15 ± 0.08 40.17 ± 6.40 15.74 ± 12.68 34.38 ± 2.29 1:9051
Alum 62.88 ± 17.06 125.75 ± 27.36 1.72 ± 0.49 38.91 ± 11.52 113.97 ± 101.98 241.50 ± 127.99 1:18102
PBS 24.13 ± 14.90 42.50 ± 38.54 1.29 ± 0.78 29.47 ± 8.49 5.88 ± .58 35.25 ± 9.36 1:6400
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to total ASC ratio.
3.3. Combined immunization with pUCpGs10 and Al(OH)3
adjuvants induce different ratios of CD19
+CD27
+and
CD19
+CD38
+ B lymphocytes
The FCM revealed the ratio of different kinds of splenic
lymphocytes. The ratio of CD19
+CD27
+ Bc e l l so ft h e
four groups were 2.06 ± 0.34, 1.15 ± 0.08, 1.72 ± 0.49,
1.29 ± 0.78(a); The ratio of CD19
+CD38
+ B cells of the
four groups are 46.42 ± 2.21, 40.17 ± 6.4, 38.91 ± 11.52,
29.47 ± 8.49(b)(Figure 2). The results show that the alu-
minum adjuvant can increase the ratio of CD19
+CD27
+(P < 0.05, F = 5.58) cells (Figure 3). However, the addi-
tion of Al (OH)3 to E1 + HVR1 did not enhance the
ratio of CD19
+CD38
+ cells further. The ratio of CD19
+CD38
+ cells with the combination of aluminum and
pUCpGs10 adjuvant is much higher than that of the
control group(without adjuvant)(P < 0.01).
3.4. Concentrations of IL-6 and IL-10 in supernatant of
cultured splenic lymphocytes in vitro
After using the ELISA assay to detect the concentration
of cytokines in the supernatants of cultured splenic lym-
phocytes from the four groups (Figure 2), It was
observed that the IL-6 and IL-10 concentrations after
the aluminum adjuvanted and adjuvanted with a
combination of aluminum and pUCpGs10 were mark-
edly higher than those of the other groups(P < 0.05).
And there are no differences between the LPS applied
and control groups (P > 0.05). So it can be excluded
that the impact of LPS mixed with the recombinant
HCV polyprotein.
3.5. Poly anti-HVR1 IgG Immunoprecipitated with 12
patients’ serum
The result showed that HCV particles in one sample
could be semi-precipitated by antiserum, that is, HCV
RNA could be detected both in the supernatant and in
the precipitate(10/12)(Figure 4).
Discussion
Given that there are no effective vaccines currently
available for HCV infection, an effective and safe immu-
nization strategy eliciting the HCV-specific humoral
response, e.g. the induction of antibody and effective B-
cell response is especially important. Accordingly, this
research used the recombinant HCV polyprotein adju-
vanted with pUCpGs10 and aluminum hydroxide. It has
been reported that inclusion of CPG7909 is associated
with a greater proliferative response of PBMC to HBsAg
at all time points following initial vaccination [39].
The present work suggests that aluminum can signifi-
cantly enhance the humoral immune response by
Figure 3 (a-b). Houmal immunity responses by CD19
+CD27
+ and CD19
+CD38
+ B cells against polyprotein with different adjuvants
measured by flow cytometry. Mice were immunized three times with the HCVE1+HVR1 polyprotein and splenocytes were isolated. The
surface of cells stained for CD19(APC), CD27(PE) or CD38 (FITC). The data are presented as the mean percentage ± SD of CD19 positive cells of
total CD27
+ or CD38
+ cells of spleens of four groups from four mice. The proportion of CD19
+ CD27
+ spleen lymphocyte of the four groups are
2.06 ± 0.34, 1.15 ± 0.08, 1.72 ± 0.49, 1.29 ± 0.78(a); The proportion of CD19
+ CD38
+ spleen lymphocyte of the four groups are 46.42 ± 2.21, 40.17
± 6.40, 38.91 ± 11.52, 29.47 ± 8.49(b);
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Moreover, the combinationo fp U C p G s 1 0w i t ha l u m i -
num hydroxide can reinforce this effect to a level, much
stronger than pUCpGs10 alone when assessed by ELISA
assay. This study prompted us to assume that one
immunological enhancement mechanism of the alumi-
num adjuvant is that it can conjugate the soluble anti-
gens as particle format, a presentation ideally suited for
internalization by APCs. It is known that the B lympho-
cyte’sr e s p o n s et oA l( O H ) 3 adjuvant is associated with
t h eg e n e s i so fam e m o r yi m m u n o l o g i cr e s p o n s el e a d i n g
to long-term immunoprotection [21]. Therefore Al(OH)
3 can promote a superior humoral immune response
compared to other adjuvants.
Based on this knowledge, the mechanisms of humoral
immunity enhancement by the pUCpGs10 and alumi-
num adjuvant can be studied. These results show that
aluminum increases the populations of specific ASCs
and the total ASCs, and when combined with
pUCpGs10. Also, the ratio of specific ASC to total ASC
can be increased as measured by the ELISPOT method.
An analysis of the flow cytometric data showed that
pUCpGs10 increases the performance of memory B cells
and aluminum adjuvant likely enhanced this response. A
similar enhancement was observed when immature B
cells were activated by the pUCpGs10 combined with
aluminum hydroxide. It can be predicted that the alumi-
num adjuvant is more potent than pUCpGs10 in enhan-
cing the quality of the specific activated immature B
cells, this will be studied in the future work. So, combin-
ing pUCpGs10 and aluminum with recombinant HCV
polyprotein produces only moderate inflammation, but
have the best effect through the most population of
antigen-specific plasma cell, memory cell and highest
titer of the specific antibody.
It can therefore to conclude that aluminum plays an
important part in achieving humoral immune responses
and persistent stimulation by pUCpGs10 adjuvants of
the production of memory B cells. From these results, it
is conceived that if the plasmid pUCpGs10 was applied
alone, it would be degraded rapidly, would only pro-
motes short term stimulation of memory B cells from
the result of the further research in future. However, the
memory B cells proliferate and differentiate into the spe-
cific ASC after receiving stimulation by antigen in the
secondary immune response. The level of antibody and
Figure 4 HCV RNA could be detected both in the supernatant and in the precipitate(10/12). Both the supernatant and the pellet were
tested for HCV RNA by enzyme immunology assay combined RT-PCR. The result show that HCV particles in one sample could be semi-
precipitated by antiserum.
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nity, and the population of specific ASCs directly corre-
lated with the level of the antibody titer. The aluminum
hydroxide adjuvant mainly enhances the level of specific
ASCs and specific antibody titer, and its effect is much
stronger than that of pUCpGs10. The pUCpGs10 stimu-
lates innate immunity and decreases the population of
non-specific ASCs, thus increasing immune efficiency.
Furthermore, the addition of pUCpGs10 does not evoke
an enhanced humoral immune reaction, but rather inhi-
bits the non-specific immune response.
The Th2 type cytokines IL-6 and IL-10 promote the
effectiveness of B cells at many levels. IL-6 stimulates B
cell differentiation and enhances the secretion of Ig and
the secondary immune response. IL-10 is an important
Th2 cytokine to inhibit the antiviral immunity and
attend the inflammation. The aluminum can enhance
the concentration of IL-10. In this study, the FCM ana-
lyses specifically show that the aluminum adjuvanted
animals have stronger enhancement of memory B cell
compared to the others. Only the combination of alumi-
num and CpG increase the effectiveness of plasma cells,
while the aluminum or CpG alone are unable to initiate
s u c har e s p o n s e .A tt h es a m et i m e ,t h eE L I S P O Ta s s a y
results confirm that CpG increases the proportion of
specific ASCs, so each adjuvant has a different and
synergistic effect on the humoral immune reaction in
mice.
10 out of 12 viruses of HCV patients’ can treat with
these immunoglobins. Using the cross-reactive and
recombinant polyprotein good respondance can be
achieved and will be considered as the new propriate
vaccine of HCV. The result of the cooperation with
SMMU (the second military medical university) is that
the neutralization activity is very good in 19 quasispecies
of 6 genotypes.
Conclusions
These results suggest that the combination of
pUCpGs10 with aluminium adjuvant may have wide
application and further studies are warranted. Relevant
and further studies are now planned in this laboratory.
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